Ampio Pharmaceuticals Inc Quick Ratio (AMPE) starting from the fourth quarter 2023 to fourth quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Ampio Pharmaceuticals inc   (NYSEAMER: AMPE)

Ampio Pharmaceuticals Inc 's Quick Ratio

AMPE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2023, Quick Ratio fell to 1.95 below Ampio Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 289 other companies have achieved higher Quick Ratio than Ampio Pharmaceuticals Inc in fourth quarter 2023. While Quick Ratio total ranking in the fourth quarter 2023 has deteriorated compared to the prior quarter from 857 to 1197.

Explain Quick Ratio?
How much Cash & cash equivalents AMPE´s has?
What are AMPE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AMPE Quick Ratio (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4
Y / Y Current Liabilities Change 146.71 % -46.85 % -54.99 % -55.36 % -82.29 %
Y / Y Cash & cash equivalent Change -67.68 % -62.25 % -69.62 % -64.1 % -62.67 %
Quick Ratio MRQ 1.95 3.35 3.25 4.45 14.85
AMPE's Total Ranking # 1197 # 857 # 812 # 732 # 230
Seq. Current Liabilities Change 10.11 % -10.84 % -7.91 % 172.89 % -76.28 %
Seq. Cash & cash equivalent Change -36.09 % -7.98 % -32.83 % -18.19 % -25.34 %



Quick Ratio fourth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 290
Healthcare Sector # 523
Overall Market # 1197


Quick Ratio Statistics
High Average Low
25.96 7.45 0.57
(Mar 31 2015)   (Mar 31 2020)




Financial Statements
Ampio Pharmaceuticals Inc 's Current Liabilities $ 2 Millions Visit AMPE's Balance sheet
Ampio Pharmaceuticals Inc 's Cash & cash equivalent $ 4 Millions Visit AMPE's Balance sheet
Source of AMPE's Sales Visit AMPE's Sales by Geography


Cumulative Ampio Pharmaceuticals Inc 's Quick Ratio

AMPE's Quick Ratio for the trailling 12 Months

AMPE Quick Ratio

 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth -41.17 % -60.65 % -47.15 % -23.36 % 28.86 %
Y / Y Cash & cash equivalent TTM Growth -65.83 % -64.55 % -54.34 % -37.41 % -6.91 %
Quick Ratio TTM 3.28 5.03 5.26 5.45 5.64
Total Ranking TTM # 3774 # 675 # 3652 # 3130 # 144
Seq. Current Liabilities TTM Growth 17.3 % -18.89 % -22.7 % -20.01 % -21.55 %
Seq. Cash & cash equivalent TTM Growth -23.56 % -22.49 % -25.36 % -22.73 % -20.71 %

Quick ratio ranking by company, industry and sector >> Back to AMPE Financial Strength Comparisons >> Go to Compare AMPE Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q4 2023 to $2.10 millions, cumulative Quick Ratio decreased to 3.28 below the Ampio Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 475 other companies have achieved higher Quick Ratio than Ampio Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 675 to 3774.

Explain Quick Ratio?
How much Cash & cash equivalents AMPE´s has?
What are AMPE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 476
Healthcare Sector # 958
Within the Market # 3774


trailing twelve months Quick Ratio Statistics
High Average Low
16.23 6.11 1.47
(March 31, 2015)   (Sep 30 2017)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Lumos Pharma Inc   5.35 $ 36.077  Millions$ 6.748  Millions
Phio Pharmaceuticals Corp  5.31 $ 8.490  Millions$ 1.599  Millions
Acelyrin Inc   5.20 $ 218.097  Millions$ 41.920  Millions
Verastem Inc   5.20 $ 137.129  Millions$ 26.380  Millions
Praxis Precision Medicines Inc   5.16 $ 81.300  Millions$ 15.749  Millions
Alx Oncology Holdings Inc  5.08 $ 182.736  Millions$ 36.001  Millions
Chemomab Therapeutics Ltd   5.02 $ 19.784  Millions$ 3.939  Millions
Indaptus Therapeutics Inc   5.00 $ 13.362  Millions$ 2.672  Millions
Bolt Biotherapeutics Inc   5.00 $ 102.189  Millions$ 20.456  Millions
Longboard Pharmaceuticals Inc   4.96 $ 48.498  Millions$ 9.774  Millions
Marker Therapeutics inc   4.91 $ 15.111  Millions$ 3.075  Millions
Pulmatrix Inc   4.90 $ 19.173  Millions$ 3.909  Millions
Carisma Therapeutics Inc   4.88 $ 77.605  Millions$ 15.908  Millions
Oramed Pharmaceuticals Inc  4.85 $ 257.991  Millions$ 53.238  Millions
Arvinas Inc   4.79 $ 1,261.000  Millions$ 263.000  Millions
Ionis Pharmaceuticals Inc   4.76 $ 2,331.201  Millions$ 489.237  Millions
Mineralys Therapeutics Inc   4.70 $ 49.304  Millions$ 10.482  Millions
Allakos Inc   4.67 $ 170.794  Millions$ 36.578  Millions
Tempest Therapeutics Inc   4.64 $ 39.230  Millions$ 8.459  Millions
Notable Labs Ltd   4.63 $ 11.825  Millions$ 2.553  Millions
Pyxis Oncology Inc   4.63 $ 119.298  Millions$ 25.759  Millions
Citius Pharmaceuticals Inc   4.59 $ 26.519  Millions$ 5.779  Millions
Scynexis Inc   4.56 $ 74.362  Millions$ 16.303  Millions
Amylyx Pharmaceuticals Inc   4.53 $ 371.362  Millions$ 82.042  Millions
Alumis inc   4.52 $ 48.952  Millions$ 10.819  Millions
Aurinia Pharmaceuticals Inc   4.52 $ 351.900  Millions$ 77.855  Millions
Liquidia Corporation  4.51 $ 83.679  Millions$ 18.550  Millions
Clearside Biomedical Inc   4.48 $ 28.920  Millions$ 6.449  Millions
Novabridge Biosciences  4.48 $ 312.412  Millions$ 69.694  Millions
Summit Therapeutics Inc   4.46 $ 71.461  Millions$ 16.040  Millions

Date modified: 2026-09-08T15:11:13+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.